Novo Nordisk Shares Drop After Trump's Statement on Drug Prices
Novo Nordisk discussed US drug pricing policies with the administration.
Trump referenced Ozempic and a fat loss drug, with UBS analysts noting price cuts were already factored in.
Novo Nordisk focused on patient access, not commenting on Trump's remarks.
Dr. Oz said GLP-1 negotiations will continue until Trump is satisfied.
Pfizer and AstraZeneca are new entrants in the GLP-1 category.
JPMorgan expects lower prices to boost sales, while BMO called market reactions overdone.
2 weeks ago